Rhythm Pharmaceuticals, Inc. (RYTM)
Last updated: 2026-10-21 22:29:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Rhythm Pharmaceuticals, Inc. (RYTM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $88.62, with a market capitalization of $6.07B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $74.50 to $122.20. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$6.07B | |
$91.02 | |
$122.20 | |
$3.04 | |
$90.20 | |
417.97K | |
674.90K | |
-- | |
$122.20 | |
$74.50 | |
-- | |
-- |
Rhythm Pharmaceuticals, Inc. (RYTM) After-Hours Stock Price
Rhythm Pharmaceuticals, Inc. (RYTM) is trading at $88.64 in after-hours trading as of 2026-10-21 21:20:00, down 1.73% ($1.56) from the regular-session close of $90.20.
After-hours trading shows how investors are pricing RYTM after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Rhythm Pharmaceuticals, Inc. (RYTM) 7-Day Stock Price Change
Over the past seven days, Rhythm Pharmaceuticals, Inc. (RYTM) moved from $89.82 to $88.62, representing a decline of 1.34% ($1.20).
The stock traded between $85.38 and $91.88 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 574.32 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
RYTM 52-Week Price Position
Position in Range: 29.6%
RYTM is currently trading at $88.62, placing it 29.6% of the way from its 52-week low of $74.50 to its 52-week high of $122.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Rhythm Pharmaceuticals, Inc. (RYTM)?
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Rhythm Pharmaceuticals, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 414 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Rhythm Pharmaceuticals, Inc. (RYTM) Stock on MEXC
Eligible investors can buy real shares of Rhythm Pharmaceuticals, Inc. (RYTM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Rhythm Pharmaceuticals, Inc. (RYTM) stock price today?
2.Is RYTM stock going up or down today?
3.What is RYTM pre-market price?
4.What is RYTM after-hours price?
5.Is RYTM stock trading now?
6.Where does RYTM sit relative to its 52-week high and low?
7.What sector is Rhythm Pharmaceuticals, Inc. in?
8.What is Rhythm Pharmaceuticals, Inc.'s market capitalization and where is it listed?
9.How is RYTM valued in terms of P/E ratio and EPS?
10.Does Rhythm Pharmaceuticals, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
RYTM Stock Calculator
Estimate the value between RYTM shares and USD.
RYTM Shares to USD
1.00 RYTM shares = 88.62 USD
Calculations are estimates based on the latest available price and are for reference only.


